ROCKVILLE, Md., Sept. 30 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that the Chairman of its Board of Directors and Chief Scientific Officer, Dr. Karl Johe, PhD, will take part in a plenary discussion entitled, “Current and Future Clinical Trials and Stem Cell Therapies,” at the World Stem Cell Summit on October 5, in Detroit, MI (http://www.worldstemcellsummit.com/summit-agenda). Dr. Johe is the creator of Neuralstem’s neural stem cell technology. The panel will be moderated by Dr. Eva Feldman, PhD, MD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System, and includes as well Dr. Jonathan Glass, MD, Professor of Neurology & Director Emory ALS Center Emory University, and Dr. Nicholas Boulis, MD, Assistant Professor Neurosurgery Emory University.
(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )
Neuralstem is currently sponsoring a Phase I trial of its spinal cord stem cells in patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig‘s disease) at the ALS Center at Emory University, in Atlanta, GA. Dr. Feldman is the Principal Investigator, Dr. Glass is the Site Principal Investigator and Dr. Boulis is the Co-Investigator and Neurosurgeon.
About Neuralstem
Neuralstem’s patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in a Phase I safety clinical trial for Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig‘s disease. In addition to ALS, the company is targeting major central nervous system diseases, including traumatic spinal cord injury, ischemic spastic paraplegia, and Huntington‘s disease. The company has also submitted an IND application to the FDA for a Phase I safety trial in chronic spinal cord injury.
Through its proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain’s capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company plans to initiate clinical trials to treat Alzheimer’s disease and major depression with its lead compound, as well as pursue additional indications, including traumatic brain injury, posttraumatic stress syndrome, stroke and schizophrenia.
For more information, please go to www.neuralstem.com
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the annual report on Form 10-K for the year ended December 31, 2009, and in its quarterly report on Form 10-Q for the period ended June 30, 2010.
SOURCE Neuralstem, Inc.
